S-1: Jupiter Neurosciences Secures $20M Equity Line, Launches Nugevia Amidst Mounting Losses

Jupiter Neurosciences, a clinical-stage pharmaceutical company, has entered a $20 million standby equity purchase agreement with Yorkville to fund its Parkinson's trial and Nugevia brand launch, despite significant and increasing net losses and a going concern warning.

Summary

• Jupiter Neurosciences, Inc. (JUNS) is a clinical-stage pharmaceutical company focusing on CNS disorders and rare diseases with its JOTROL product, and is expanding into the consumer longevity market with its Nugevia brand.
• The company has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD (Yorkville) for up to $20 million in common stock sales, at the company's discretion, over a 24-month term.
• Under the SEPA, Jupiter Neurosciences received a first pre-paid advance of $3.72 million on October 27, 2025, in exchange for a $4.0 million convertible promissory note, with a second tranche of $1.86 million expected upon registration effectiveness and stockholder approval.
• The SEPA allows for the resale of up to 10,000,000 shares of common stock by Yorkville, comprising 131,909 commitment shares, up to 4,000,000 conversion shares, and up to 5,868,091 advance shares.
• Proceeds from the SEPA will primarily support the Phase II trial of JOTROL for Parkinson's Disease and accelerate marketing and sales growth for the Nugevia.com nutritional product line.
• The company reported a net loss of $6,069,866 for the nine months ended September 30, 2025, a significant increase from $911,998 for the same period in 2024.
• Operating cash flow was negative $3,045,713 for the nine months ended September 30, 2025, compared to negative $215,225 for the same period in 2024.
• As of September 30, 2025, the accumulated deficit since inception totaled $32,091,995.
• Management has concluded that historical recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern, a concern also noted by its auditor for fiscal years 2023 and 2024.
• Research and development expenses increased by 600% to $2,042,890 for the nine months ended September 30, 2025, primarily due to a three-year service agreement for product development and distribution in Southeast Asia and procurement of clinical trial supplies for the Parkinson's program.
• General and administrative expenses increased by 202% to $4,057,046 for the nine months ended September 30, 2025, driven by full employee salaries, bonus accruals, increased legal and professional fees due to Nasdaq listing, and higher insurance and consulting fees.
• The Nugevia brand, launched in March 2025, offers premium nutritional supplements (GLO, MND, PWR) leveraging JOTROL's nine-fold increased bioavailability, with shipments expected in Q4 2025 via a direct-to-consumer model.
• The company plans to initiate a Phase IIa clinical study for Parkinson's Disease in Q4 2025, with results anticipated 12 months later, and aims to explore other CNS indications like Mild Cognitive Impairment (MCI) and Alzheimer's disease.
• Jupiter Neurosciences holds an exclusive worldwide license for JOTROL from Aquanova AG, with patents granted in the U.S., EU, Japan, China, and Hong Kong, expiring in 2036.

Sentiment

Score: 3

Explanation: The company is in a precarious financial position with significant and increasing net losses, negative cash flow, and a going concern warning. While the SEPA provides a lifeline and strategic initiatives like Nugevia and the Parkinson's trial offer long-term potential, the immediate financial distress and substantial dilution risk weigh heavily on the sentiment.

Positives

• Secured a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $20 million, providing a potential source of capital.
• Successfully launched the Nugevia brand of premium nutritional supplements, leveraging proprietary JOTROL technology for enhanced bioavailability, targeting the rapidly growing longevity and wellness market.
• JOTROL, the proprietary resveratrol formulation, has demonstrated significantly improved bioavailability (over nine times higher) in Phase I studies without severe adverse events, addressing a major challenge for resveratrol-based therapeutics.
• JOTROL has shown positive effects on oxidative stress, inflammation, and mitochondrial function in preclinical and human studies, indicating broad therapeutic potential.
• Received patent approvals for JOTROL in key Asian markets (Hong Kong, China, Japan), generating significant interest from Asian organizations and leading to strategic service agreements for product development and distribution in Southeast Asia.
• Planning to initiate a Phase IIa clinical study for Parkinson's Disease in Q4 2025, a significant step in advancing its pharmaceutical pipeline.
• Obtained Orphan Drug Designation (ODD) for JOTROL in Friedreich's ataxia, which provides financial incentives and market exclusivity potential.
• Management and scientific advisory board possess extensive experience in drug development and regulatory affairs for rare diseases and CNS disorders.

Negatives

• Incurred significant and increasing net losses, with $6,069,866 for the nine months ended September 30, 2025, compared to $911,998 for the same period in 2024.
• Experienced substantial negative cash flow from operating activities, totaling $3,045,713 for the nine months ended September 30, 2025, and $3,911,004 for the year ended December 31, 2024.
• Has an accumulated deficit of $32,091,995 as of September 30, 2025, indicating a history of unprofitability.
• Management and auditors have raised substantial doubt about the company's ability to continue as a going concern due to historical recurring losses and dependence on external financing.
• The SEPA with Yorkville, while providing capital, involves significant potential dilution to existing stockholders, as up to 10,000,000 shares are registered for resale, representing approximately 29.0% of outstanding shares and 106.5% of non-affiliate held shares as of November 25, 2025.
• High R&D expenses ($2,042,890 for 9M 2025) and G&A expenses ($4,057,046 for 9M 2025) are consuming cash rapidly.
• The company has no products approved for commercial sale in its pharmaceutical segment and has not generated any revenue from product sales to date.
• Past grant applications for a Phase II Alzheimer's trial were unsuccessful, indicating challenges in securing non-dilutive funding for key programs.
• The global nutraceutical market for Nugevia is highly competitive, with established players and consumer skepticism regarding resveratrol's efficacy, requiring significant marketing and differentiation efforts.
• Reliance on third-party manufacturers and CROs introduces supply chain vulnerabilities and risks of unsatisfactory performance or non-compliance with regulatory standards.

Risks

• We have not generated any revenue from product sales to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future.
• Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2023 and 2024.
• We will require substantial additional capital to finance our operations; if we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
• Raising additional capital may cause substantial dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
• The launch of the Nugevia brand exposes the Company to a number of business and operational risks that could materially and adversely impact its business, including intense competition and consumer skepticism.
• Our business and future prospects with the Nugevia brand and our pharmaceutical products are significantly dependent on our exclusive, worldwide license agreement with Aquanova; any adverse development related to this license agreement could materially and adversely affect our operations, financial condition, and results of operations.
• If the Company or its suppliers fails to comply with FDA or other regulations, it could result in enforcement actions or delays in the Nugevia brand product launch.
• We are substantially dependent on the success of our lead product candidate, JOTROL, which will be undergoing Phase II clinical trials. If we are unable to complete development of, obtain approval for and commercialize JOTROL for one or more indications in a timely manner, our business will be harmed.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome. The clinical trials of our product candidate JOTROL may not demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or other comparable foreign regulatory authorities or otherwise produce positive results and the results of preclinical studies and early clinical trials may not be predictive of future results.
• Our product candidates may cause serious adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or INDs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
• The patient population suffering from MPS I, Friedreich's ataxia, and MELAS is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be adversely affected.
• Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
• Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability could have an adverse effect on our business and financial condition.
• The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.
• Our success depends on our ability to protect our intellectual property and our proprietary technologies, including JOTROL, and any loss or challenge to these rights could materially adversely affect our financial condition and results of operations.
• We rely, and expect to continue to rely, on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies, which may harm our business.
• Our computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
• The price of our common stock could be subject to rapid and substantial volatility, especially as a relatively small-capitalization company with a small public float.

Future Outlook

The company plans to initiate a Phase IIa clinical study for JOTROL in Parkinson's Disease in the fourth quarter of 2025, with results expected 12 months later. Following this, it aims to explore other CNS indications such as Mild Cognitive Impairment (MCI) and Alzheimer's disease. The Nugevia consumer product line, focusing on longevity and healthspan, is expected to begin shipments in the fourth quarter of 2025 through a direct-to-consumer model, with plans for international marketing. The company intends to seek stockholder approval at its December 19, 2025 annual meeting to issue shares in excess of the Nasdaq Exchange Cap under the SEPA, which would enable it to access the full $20 million commitment from Yorkville. Future operations are dependent on raising additional funds through equity or debt, licensing intellectual property, or strategic partnerships.

Management Comments

• Management believes that JOTROL, based on Phase I study results, has resolved the major obstacle of resveratrol's poor bioavailability, enabling therapeutically effective doses without severe gastrointestinal side effects.
• Management believes that results from preclinical studies indicate Parkinson's Disease might be the best target for treatment and financial opportunity among multiple indications for JOTROL.
• Management believes that the strategy with service agreements in Asia is cost-effective and has the possibility to accelerate out-licensing deals in South-East Asian territories.
• Management believes that Nugevia's launch is a pivotal move to monetize proprietary science, support ongoing clinical trials, and capture a share of the booming longevity market.
• Management believes that the focus on a new product based on resveratrol with higher bioavailability, JOTROL, will enable the company to utilize the same product for several indications, subject to FDA approval, providing multiple opportunities for regulatory approval.
• Management believes that oral delivery of medications is a physician and patient preferred treatment compared with injections and infusions and expects the product to have an attractive and affordable price point for reimbursers and patients.
• Management believes that its core management team structure has proven experience in utilizing outside resources, allowing efficient execution of several programs simultaneously in a very cost-effective way.

Industry Context

Jupiter Neurosciences operates in the highly competitive biotechnology and biopharmaceutical industries, targeting CNS disorders and rare diseases, while also expanding into the consumer longevity and wellness market. The global longevity market is projected to grow from $5.3 trillion in 2023 to $8 trillion by 2030, driven by aging demographics and demand for science-backed wellness solutions. The company's focus on neuroinflammation and metabolic dysfunction aligns with key aging accelerators identified in industry reports. In the pharmaceutical space, it faces intense competition from major players developing treatments for Parkinson's, Alzheimer's, and rare diseases, necessitating strong differentiation and successful clinical outcomes. The nutraceutical market is also highly competitive, requiring Nugevia to overcome consumer skepticism and establish credibility through its proprietary JOTROL technology.

Comparison to Industry Standards

• In Parkinson's Disease, the company competes with widely used treatments like levodopa/carbidopa, which has been a standard since the late 1960s.
• For Alzheimer's disease, competitors include Biogen's Aduhelm, Eli Lilly's donanemab, Eisai and Biogen's Leqembi, Cognition Therapeutics' CT1812 (Phase II), and Anavex Life Sciences' Anavex 2-73 (Phase III).
• In MPS-1, competitors include Sanofi Genzyme's Aldurazyme (standard enzyme replacement therapy), RegenexBio's RGX-111 (gene therapy), and Sigilon Therapeutics' SIG-005 (genetically modified cell line).
• For Friedreich's ataxia, Reata Pharmaceuticals' Omaveloxolone (SKYCLARYS) received approval in 2023, and Minoryx Therapeutics' MIN-102 (Phase II) and Larimar Therapeutics' CTI-1601 (Phase I) are also in development.
• In MELAS, Cyclerion Therapeutics is advancing CY643 (Phase 1B), and Abliva AB is developing KL1333 (Phase 2/3, orphan drug designation in US/EU).
• Nugevia competes in the global nutraceutical market (valued at $458.55 billion in 2024, projected to reach $8 trillion by 2030) against established players like Nestlé Health Science, Amway, ChromaDex (Tru-Niagen), Novos, Timelines (urolithin A), and Tally Health, many of whom also use advanced delivery systems like liposomal and micellar technologies.

Corporate Governance

Legal Proceedings

• Settled a civil action with Tiberend Strategic Advisors for non-payment under a services agreement, resulting in a $150,000 convertible promissory note issued in March 2023, which was fully repaid by December 2024.

Related Party Transactions

• The CEO, Christer Rosn, loaned the company working capital since inception. The outstanding balance was $146,432 as of September 30, 2025 and December 31, 2024, accruing 3% interest per year. This loan was fully repaid on October 1, 2025, for $150,782 (principal + accrued interest).
• As of September 30, 2025, $136,105 was payable to Titan Advisory Services LLC, a company wholly owned by the CFO, Saleem Elmasri, for executive finance and corporate support services under a Master Services Agreement.
• In March 2024, a former executive forgave $100,000 of accrued compensation in exchange for 49,605 stock options and 7,500 restricted stock units, resulting in a $40,000 gain for the company.
• On September 29, 2023, various employees and board members agreed to forgive $4,189,626 of accrued compensation in exchange for 2,353,661 stock options and 1,399,834 restricted stock units.
• On December 18, 2023, an amendment to the accrued compensation forgiveness occurred, where cash bonuses of $513,013 for employees and $70,200 for board members were forgiven, and equity grants were amended to vest fully on the amendment's effective date or upon IPO/change of control.

Stakeholder Impact

• **Shareholders:** Face significant potential dilution from the Standby Equity Purchase Agreement (SEPA) with Yorkville, as up to 10,000,000 shares are registered for resale, representing a substantial percentage of outstanding shares. The company's going concern warning also poses a risk to investment value. Stockholders will vote on increasing the share issuance limit under the SEPA.
• **Employees/Executives:** Executive salaries were deferred and reduced in 2023 to conserve cash, though they resumed full payment in December 2024. Accrued bonuses totaling $449,000 for officers and a third-party advisor are contingent on the company maintaining $3.5 million in cash, indicating potential delays in payment. Equity grants are a significant part of compensation, aligning interests with company performance.
• **Customers (Nugevia):** Will benefit from the launch of new longevity and wellness products leveraging JOTROL's enhanced bioavailability, with initial shipments expected in Q4 2025. The direct-to-consumer model aims to provide direct access to these science-backed solutions.
• **Patients (JOTROL):** The planned Phase IIa clinical trial for Parkinson's Disease offers hope for a new therapeutic option for CNS disorders. Continued development of JOTROL for rare diseases like MPS I, Friedreich's ataxia, and MELAS could provide much-needed treatments for small patient populations.
• **Creditors:** The company's dependence on external financing and its going concern status indicate elevated risk for creditors. The repayment of the CEO's loan and other convertible notes demonstrates efforts to manage debt obligations.

Next Steps

• Initiate Phase IIa clinical study for JOTROL in Parkinson's Disease in Q4 2025, with results anticipated 12 months thereafter.
• Begin shipments of Nugevia brand products in Q4 2025 through a direct-to-consumer (DTC) model.
• Seek requisite stockholder approval at the 2025 Annual Stockholders Meeting (December 19, 2025) to issue shares in excess of the Nasdaq Exchange Cap under the SEPA.
• File additional Registration Statements with the SEC to register more shares for resale by Yorkville if the company elects to sell more than the initial 10,000,000 shares under the SEPA.
• Continue to explore other CNS indications, such as Mild Cognitive Impairment (MCI) and Alzheimer's disease, following the Parkinson's study.
• Reapply for a smaller grant ($2.5 million) for a proof-of-concept study focusing on JOTROL's effect on validated biomarkers, utilizing data from the Phase IIa Parkinson's Disease study.
• Expand Nugevia distribution to Europe, the Middle East, and Southeast Asia through regional partnerships.
• Continue business development activities in the Asian region through service agreements to accelerate product development and potential out-licensing deals.

Key Dates

Recommendation

The company faces severe financial challenges, including significant and increasing net losses, substantial negative cash flow, and an accumulated deficit of over $32 million. Both management and the auditor have expressed substantial doubt about the company's ability to continue as a going concern. While the Standby Equity Purchase Agreement (SEPA) with Yorkville provides a potential capital infusion, it comes with a high risk of significant dilution to existing shareholders, as up to 10 million shares are registered for resale, representing over 100% of non-affiliate held shares. The company's pharmaceutical pipeline is in early clinical stages, with no approved products or revenue from sales, and past grant applications for key programs have been unsuccessful. The launch of the Nugevia brand is a positive step but operates in a highly competitive market with inherent regulatory and commercialization risks. Given the profound financial distress, high burn rate, and the dilutive nature of the primary funding mechanism, the investment carries extreme risk, making a 'strong sell' recommendation appropriate for seasoned investors.

Keywords

Jupiter Neurosciences, JOTROL, Nugevia, Resveratrol, Parkinson's Disease, Alzheimer's Disease, Mild Cognitive Impairment, Rare Diseases, MPS I, Friedreich's Ataxia, MELAS Syndrome, Neuroinflammation, Longevity, Nutraceuticals, Biotechnology, Pharmaceuticals, SEC Filing, S-1, Standby Equity Purchase Agreement, Convertible Notes, Clinical Trials, Drug Development, Bioavailability, Orphan Drug Designation, Nasdaq